Neil A. Ettinger
Experienced in Bronchiectasis

Dr. Neil A. Ettinger

Pulmonary Medicine | Intensive Care Medicine | Pain Medicine
Physician Specialists Of St Lukes LLC
232 S Woods Mill Rd, 
Chesterfield, MO 
Accepting New Patients
Offers Telehealth
Experienced in Bronchiectasis
Physician Specialists Of St Lukes LLC
232 S Woods Mill Rd, 
Chesterfield, MO 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Neil Ettinger is a Pulmonary Medicine specialist and an Intensive Care Medicine provider in Chesterfield, Missouri. Dr. Ettinger is rated as an Experienced provider by MediFind in the treatment of Bronchiectasis. His top areas of expertise are Pulmonary Fibrosis, Acute Interstitial Pneumonia, Idiopathic Pulmonary Fibrosis, Advanced Bronchoscopy, and Gastrostomy. Dr. Ettinger is currently accepting new patients.

His clinical research consists of co-authoring 5 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Pulmonary Medicine
Intensive Care Medicine
Pain Medicine
Licenses
Critical Care Medicine in MO
Hospital Affiliations
St Luke's Des Peres Hospital
St Lukes Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Dean Health
  • EPO
  • HMO
  • POS
  • PPO
Essence Healthcare
  • INSURANCE PLAN
  • MEDICARE MAPD
Health Alliance
  • EPO
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Home State Health
  • EPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
MetLife
  • PPO
Oscar
  • EPO
  • HMO
  • PPO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 17 Less Insurance Carriers -

Locations

PHYSICIAN SPECIALISTS OF ST LUKES LLC
232 S Woods Mill Rd, Chesterfield, MO 63017

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A 52-week, Randomised, Double-blind, Double-dummy, Parallel Group, Multi-centre, Non-inferiority Study Assessing Exacerbation Rate, Additional Measures of Asthma Control and Safety in Adult and Adolescent Severe Asthmatic Participants With an Eosinophilic Phenotype Treated With GSK3511294 Compared With Mepolizumab or Benralizumab
A 52-week, Randomised, Double-blind, Double-dummy, Parallel Group, Multi-centre, Non-inferiority Study Assessing Exacerbation Rate, Additional Measures of Asthma Control and Safety in Adult and Adolescent Severe Asthmatic Participants With an Eosinophilic Phenotype Treated With GSK3511294 Compared With Mepolizumab or Benralizumab
Enrollment Status: Completed
Publish Date: October 15, 2025
Intervention Type: Biological, Drug, Device
Study Drugs: Depemokimab, Mepolizumab, Benralizumab
Study Phase: Phase 3
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis (TETON-1)
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis (TETON-1)
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2025
Intervention Type: Device, Drug
Study Drug: Treprostinil
Study Phase: Phase 3
A Phase 2, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of 2 mg and 4 mg SUVN-G3031 Compared to Placebo in Patients With Narcolepsy With and Without Cataplexy
A Phase 2, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of 2 mg and 4 mg SUVN-G3031 Compared to Placebo in Patients With Narcolepsy With and Without Cataplexy
Enrollment Status: Completed
Publish Date: January 13, 2025
Intervention Type: Drug
Study Drug: SUVN-G3031
Study Phase: Phase 2
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Enrollment Status: Terminated
Publish Date: September 19, 2024
Intervention Type: Drug
Study Drug: Pamrevlumab
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled Dose Escalation and Verification Clinical Study to Assess the Safety and Efficacy of Pulsed Inhaled Nitric Oxide (iNO) in Subjects at Risk of Pulmonary Hypertension Associated With Pulmonary Fibrosis on Long Term Oxygen Therapy (Part 1 and Part 2) - REBUILD
A Randomized, Double-Blind, Placebo-Controlled Dose Escalation and Verification Clinical Study to Assess the Safety and Efficacy of Pulsed Inhaled Nitric Oxide (iNO) in Subjects at Risk of Pulmonary Hypertension Associated With Pulmonary Fibrosis on Long Term Oxygen Therapy (Part 1 and Part 2) - REBUILD
Enrollment Status: Terminated
Publish Date: July 27, 2023
Intervention Type: Combination product
Study Drug: INOpulse
Study Phase: Phase 3
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) in Heart Failure With Preserved Ejection Fraction (HFpEF)
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) in Heart Failure With Preserved Ejection Fraction (HFpEF)
Enrollment Status: Terminated
Publish Date: November 10, 2020
Intervention Type: Drug
Study Phase: Phase 3
An Open-label Extension Study of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Heart Failure With Preserved Ejection Fraction (HFpEF) - A Long-term Follow-up to Study TDE-HF-301
An Open-label Extension Study of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Heart Failure With Preserved Ejection Fraction (HFpEF) - A Long-term Follow-up to Study TDE-HF-301
Enrollment Status: Terminated
Publish Date: October 22, 2020
Intervention Type: Drug
Study Phase: Phase 3
View 6 Less Clinical Trials

5 Total Publications

Meaningful Endpoints for Idiopathic Pulmonary Fibrosis (IPF) Clinical Trials: Emphasis on 'Feels, Functions, Survives'. Report of a Collaborative Discussion in a Symposium with Direct Engagement from Representatives of Patients, Investigators, the National Institutes of Health, a Patient Advocacy Organization, and a Regulatory Agency.
Meaningful Endpoints for Idiopathic Pulmonary Fibrosis (IPF) Clinical Trials: Emphasis on 'Feels, Functions, Survives'. Report of a Collaborative Discussion in a Symposium with Direct Engagement from Representatives of Patients, Investigators, the National Institutes of Health, a Patient Advocacy Organization, and a Regulatory Agency.
Journal: American journal of respiratory and critical care medicine
Published: January 04, 2024
Similar Doctors
Distinguished in Bronchiectasis
Dr. Umer H. Siddiqui
Pulmonary Medicine
Distinguished in Bronchiectasis
Dr. Umer H. Siddiqui
Pulmonary Medicine

Mercy Clinic Pulmonology Washington LLC

521 Anwijo Way, 
Warrenton, MO 
 (36.2 miles away)
636-231-6245
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Umer Siddiqui is a Pulmonary Medicine provider in Warrenton, Missouri. Dr. Siddiqui is rated as a Distinguished provider by MediFind in the treatment of Bronchiectasis. His top areas of expertise are Lung Nodules, Lung Metastases, Chronic Obstructive Pulmonary Disease (COPD), and Bronchiectasis. Dr. Siddiqui is currently accepting new patients.

Distinguished in Bronchiectasis
Dr. Amjad Horani
Pediatric Pulmonology | Pediatrics | Pulmonary Medicine
Distinguished in Bronchiectasis
Dr. Amjad Horani
Pediatric Pulmonology | Pediatrics | Pulmonary Medicine

Washington University

1 Childrens Pl, 
Saint Louis, MO 
 (13.0 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Amjad Horani is a Pediatric Pulmonologist and a Pediatrics provider in Saint Louis, Missouri. Dr. Horani is rated as a Distinguished provider by MediFind in the treatment of Bronchiectasis. His top areas of expertise are Kartagener Syndrome, Situs Inversus, Ciliary Dyskinesia-Bronchiectasis, and Bronchiectasis. Dr. Horani is currently accepting new patients.

Distinguished in Bronchiectasis
Dr. Daniel B. Rosenbluth
Pulmonary Medicine
Distinguished in Bronchiectasis
Dr. Daniel B. Rosenbluth
Pulmonary Medicine

Washington University

1 Barnes Jewish Hospital Plz, 
Saint Louis, MO 
 (12.9 miles away)
314-747-3000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Daniel Rosenbluth is a Pulmonary Medicine provider in Saint Louis, Missouri. Dr. Rosenbluth is rated as a Distinguished provider by MediFind in the treatment of Bronchiectasis. His top areas of expertise are Cystic Fibrosis, Bronchiectasis, Secondary Immunodeficiency (SID), and Lung Metastases. Dr. Rosenbluth is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Ettinger's expertise for a condition
ConditionClose
    View All 10 Distinguished Conditions
    View All 13 Advanced Conditions
    View All 31 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile